The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“High-Grade Glioma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the High-Grade Glioma Market.

Some of the key takeaways from the High-Grade Glioma Pipeline Report: 

• Companies across the globe are diligently working toward developing novel High-Grade Glioma treatment therapies with a considerable amount of success over the years. 

• High-Grade Glioma companies working in the treatment market are Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others, are developing therapies for the High-Grade Glioma treatment 

• Emerging High-Grade Glioma therapies in the different phases of clinical trials are- ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others are expected to have a significant impact on the High-Grade Glioma market in the coming years.   

• In November 2023, BioMimetix revealed that its BMX-001, when used alongside radiotherapy and temozolomide, extended the median survival period by 6.6 months among glioma patients. Additionally, the treatment showed promise in mitigating radiation-induced cognitive impairments and enhancing white matter integrity. These findings stem from the Phase II trial (NCT02655601) conducted by the clinical-stage biotech, focusing on the evaluation of BMX-001 in patients with high-grade glioma (HGG).

• In January 2023, “ONC201 for the Treatment of Newly Diagnosed H3 K27Mmutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study” is the name of the experiment that Chimerix started.

• In February 2023, According to Plus Therapeutics, the FDA is involved in the company’s planned Investigational New Drug (IND) application for the treatment of pediatric patients with high-grade glioma and ependymoma.

• In January 2023, A clinical update from the ongoing Phase I trial investigating INB-200 in patients with newly diagnosed GBM was released by IN8bio, Inc., a clinical-stage biopharmaceutical firm researching novel gamma-delta T cell treatments. The business also stated pipeline plans for 2023. In the first data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM), all three patients exceeded the median progression-free survival (PFS) of seven months, with two contin ued responses extending beyond 1.5 years and 1.2 years progression-free, respectively. Along with concluding Cohort 3’s participation in the Phase I study, the business intends to provide topline results and additional data from a longer-term follow-up.

• In September 2022, “Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication” is the name of the trial that Chimerix started. This multicenter, phase 3 controlled trial is randomized, open-label, and randomized. Its primary goal is to compare the efficacy of ONC201 to everolimus, and then to historical controls.

• In December 2022, Chimerix announced that individuals with H3 K27M-mutant gliomas could now begin the ONC201 Phase III ACTION trial.

• In June 2022, VBI-1901 was given orphan drug designation (ODD) by the US FDA to treat GBM.

High-Grade Glioma Overview

High-grade glioma refers to a type of brain tumor that originates from glial cells in the brain. These tumors are classified as high-grade due to their aggressive nature and fast growth rate. They are further categorized based on their cell type and characteristics, with glioblastoma being the most common and aggressive form of high-grade glioma. High-grade gliomas are often difficult to treat and have a poor prognosis, as they tend to infiltrate surrounding brain tissue, making complete surgical removal challenging

Get a Free Sample PDF Report to know more about High-Grade Glioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight

Emerging High-Grade Glioma Drugs Under Different Phases of Clinical Development Include:

• ONC201: Chimerix

• BMX-001: BioMimetix

• OKN-007: Oblato, Inc.

• Lisavanbulin: Basilea Pharmaceutica

• Terameprocol: Erimos Pharmaceuticals

• Zotiraciclib: Adastra Pharmaceuticals/S*Bio

• PTC596: PTC Therapeutics

• OS2966: OncoSynergy

• CAN 3110: Candel Therap

• DSP 0390: Sumitomo Pharma Oncology, Inc.

• Terameprocol: Erimos Pharmaceuticals

• Lenvatinib: Eisai Inc.

• PVSRIPO: Istari Oncology, Inc.

• BMX-001: BioMimetix Pharma

High-Grade Glioma Route of Administration

High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Infusion

• Intradermal

• Intramuscular

• Intranasal

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Molecule Type

High-Grade Glioma Molecule Type

High-Grade Glioma Products have been categorized under various Molecule types, such as

• Gene therapies

• Small molecule

• Vaccines

• Polymers

• Peptides

• Monoclonal antibodies

• Product Type

High-Grade Glioma Pipeline Therapeutics Assessment

• High-Grade Glioma Assessment by Product Type

• High-Grade Glioma By Stage and Product Type

• High-Grade Glioma Assessment by Route of Administration

• High-Grade Glioma By Stage and Route of Administration

• High-Grade Glioma Assessment by Molecule Type

• High-Grade Glioma by Stage and Molecule Type

DelveInsight’s High-Grade Glioma Report covers around 150+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further High-Grade Glioma product details are provided in the report. Download the High-Grade Glioma pipeline report to learn more about the emerging High-Grade Glioma therapies

Some of the key companies in the High-Grade Glioma Therapeutics Market include:

Key companies developing therapies for High-Grade Glioma are – Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.

High-Grade Glioma Pipeline Analysis:

The High-Grade Glioma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of High-Grade Glioma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for High-Grade Glioma Treatment.

• High-Grade Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• High-Grade Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the High-Grade Glioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about High-Grade Glioma drugs and therapies

High-Grade Glioma Pipeline Market Drivers

• Increasing the prevalence of High Grade Glioma, increase in the accessibility to more options for the treatment and diagnosis of a high-grade tumor are some of the important factors that are fueling the High-Grade Glioma Market.

High-Grade Glioma Pipeline Market Barriers

• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the High-Grade Glioma Market growth.

Scope of High-Grade Glioma Pipeline Drug Insight    

• Coverage: Global

• Key High-Grade Glioma Companies: Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others

• Key High-Grade Glioma Therapies: ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others

• High-Grade Glioma Therapeutic Assessment: High-Grade Glioma current marketed and High-Grade Glioma emerging therapies

• High-Grade Glioma Market Dynamics: High-Grade Glioma market drivers and High-Grade Glioma market barriers 

Request for Sample PDF Report for High-Grade Glioma Pipeline Assessment and clinical trials

Table of Contents

1. High-Grade Glioma Report Introduction

2. High-Grade Glioma Executive Summary

3. High-Grade Glioma Overview

4. High-Grade Glioma- Analytical Perspective In-depth Commercial Assessment

5. High-Grade Glioma Pipeline Therapeutics

6. High-Grade Glioma Late Stage Products (Phase II/III)

7. High-Grade Glioma Mid Stage Products (Phase II)

8. High-Grade Glioma Early Stage Products (Phase I)

9. High-Grade Glioma Preclinical Stage Products

10. High-Grade Glioma Therapeutics Assessment

11. High-Grade Glioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. High-Grade Glioma Key Companies

14. High-Grade Glioma Key Products

15. High-Grade Glioma Unmet Needs

16 . High-Grade Glioma Market Drivers and Barriers

17. High-Grade Glioma Future Perspectives and Conclusion

18. High-Grade Glioma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/